CELG - IPO Update: Keros Therapeutics Proposes IPO Terms
Quick Take
Keros Therapeutics (KROS) intends to raise $75 million from the sale of its common stock, per an amended S-1/A regulatory filing.
The company is advancing a pipeline of drug treatment candidates for hematological and musculoskeletal diseases.
KROS is entering Phase 2 trials for its lead candidate and has a collaboration partnership with Novo Nordisk on a pre-clinical target.
For life science investors with at least an 18 - 24-month hold time frame, the IPO may present a quality opportunity.
Company & Technology
Lexington, Massachusetts-based Keros was founded to develop therapies